Marc J. M. Bonten
Utrecht University
664 Papers
2.8K Citations
Marc J. M. Bonten is an academic researcher from Utrecht University. The author has contributed to research in topics: Medicine & Intensive care. The author has an hindex of 88, co-authored 600 publications. Previous affiliations of Marc J. M. Bonten include University Medical Center Utrecht & Oklahoma State University Center for Health Sciences.
Chat about Author
Papers
For whom should we use selective decontamination of the digestive tract
TL;DR: Recent studies show that in ICUs with low levels of antibiotic resistance, SDD and SOD improved patient outcome and reduced infections and carriage with antibiotic-resistant pathogens.
Sequence-based epidemiology of an OXA-48 plasmid during a hospital outbreak.
Laura Hidalgo,Mark de Been,Malbert R. C. Rogers,Anita C. Schürch,Jelle Scharringa,Anneke van der Zee,Marc J. M. Bonten,Ad C. Fluit +7 more
TL;DR: These findings provide strong evidence for both within-host interspecies and between-host dissemination of plasmid-based OXA-48 during a nosocomial outbreak and exemplify the complex epidemiology of carbapenemase-producing Enterobacteriaceae (CPE).
Designing Surveillance of Healthcare-Associated Infections in the Era of Automation and Reporting Mandates.
TL;DR: The choice among (automated) surveillance approaches should be guided by the intended aim and scale of surveillance (eg, research, in-hospital quality improvement, national surveillance, or pay-for-performance mandates), as this choice dictates subsequent methods, important performance characteristics, and suitability of the data generated for the different applications.
Fighting antibiotic resistance in the intensive care unit using antibiotics
TL;DR: An overview of selective oropharyngeal and digestive tract decontamination, decolonization of methicillin-resistant Staphylococcus aureus and antibiotic rotation as strategies to modulate antibiotic resistance in the intensive care unit is provided.
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance
Tomislav Kostyanev,Marc J. M. Bonten,Seamus O'Brien,Helen C. Steel,S Ross,Bruno François,Evelina Tacconelli,Mathias Winterhalter,R A Stavenger,Anders Karlén,Stéphan Juergen Harbarth,J Hackett,Hasan S. Jafri,Cuong Vuong,Alasdair P. MacGowan,A.T. Witschi,Gerhild Angyalosi,J. S. Elborn,R deWinter,Herman Goossens +19 more
TL;DR: Seven projects have been launched within the ND4BB programme, an Innovative Medicines Initiative, to boost the fight against ABR at every level from basic science and drug discovery, through clinical development to new business models and responsible use of antibiotics.